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Abstract
Background: Anaplastic pancreatic cancer (APC) cell lines have been scarcely established.
Methods: The morphology, gene expressions, karyotyping and epithelial-mesenchymal transition markers of newly
established APC cell lines OCUP-A1 and OCUP-A2 were analyzed. Their abilities of proliferation under normoxia and
hypoxia, migration and invasion were compared to 4 commercially available pancreatic ductal adenocarcinoma (PDA)
cell lines. Their induction of angiogenesis, stem-like cell population and subcutaneous tumor growth in nude mice
were estimated, comparing 2 PDA cell lines examined here.
Results: OCUP-A1 and OCUP-A2 cells continuously grew with spindle and polygonal shapes, respectively. Gene analysis
revealed 9 gene mutations including KRAS and TP53. Karyotyping clarified numerical structural abnormalities in both cells.
Loss of E-cadherin and expression of vimentin in both cell lines were observed. The doubling time of both cell lines was
approximately 20 h. Proliferation, migration and invasion abilities were not notable compared to other PDA cell lines.
However stem-like cell population of both cell lines was superior to a part of PDA cell lines. Moreover OCUP-A1 showed
stronger hypoxia tolerance and induction of angiogenesis than other PDA cell lines. The tumorigenicity in vivo of
OCUP-A2 was stronger than conventional PDA cell lines.
Conclusions: The OCUP-A1 and OCUP-A2 cell lines of rare malignancies might be useful for investigating the
biology of pancreatic cancer.
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Background
Although the number of treatment strategies has been
increasing for pancreatic ductal adenocarcinoma (PDA),
it still has poor prognosis. The 5-year survival rate is <5 %,
and the outcomes have not changed for almost 50 years
[1, 2]. Anaplastic pancreatic cancer (APC) is a rare histo-
pathological type of PDA. APC is one of the synonyms for
undifferentiated carcinoma [3], and is classified as grade 4
in the World Health Organization classification [4]. In
Japan, approximately 0.1 % of all pancreatic cancer was
this type [5]. In general, the percentage reported ranged
from approximately 2–12 % [6–8]. Several studies have
found that APC frequently occurs in patients with an
average age of 60 years [8, 9]. The incidence of this tumor
is three times higher in men than in women [8]. Common
clinical manifestations are abdominal pain, fatigue, and
anorexia [8]. Computed tomography (CT) has shown that
the tumor is likely to show low density in the central
region and high density in the marginal region [3].
These findings suggest that the central area is necrotic,
and the marginal area has abundant blood flow [3]. Only
surgical resection offers the possibility of a complete cure
[3]. Systemic chemotherapy administered for conventional
* Correspondence: kenjiro@med.osaka-cu.ac.jp
†Equal contributors
1Department of Surgical Oncology, Osaka City University Graduate School of
Medicine, 4-3, 1-chome, Asahimachi, Abeno-ku, Osaka city, Osaka 545-8585,
Japan
Full list of author information is available at the end of the article
© 2016 Miura et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Miura et al. BMC Cancer  (2016) 16:268 
DOI 10.1186/s12885-016-2297-y
PDA is generally not effective [10]. The overall survival of
APC is several months [11]. This is less than seen with
conventional PDA [3]. Regarding APC, not much is yet
known about its biological features. An effective treatment
modality has not been identified for either APC or PDA.
In the present study, we succeeded in establishing two cell
lines of APC, and characterized the properties that might
lead to successful therapy. These cell lines were useful for
researching the basic characteristics of pancreatic cancer
because the two established cell lines had several features





A man in his 60s with abdominal pain was suspected as
having pancreatic cancer, as seen on CT. The values of car-
cinoembryonic antigen (CEA), cancer antigen (CA) 19–9,
SPan-1 and DUPAN-2 were 3.1 ng/mL, 4 U/mL, >3 U/mL
(reference value), and >25 U/mL (reference value), respect-
ively. The patient underwent distal pancreatectomy with
resection of the portal vein which accompanied a tumor
embolism. The pathological stage was T3N1M0, UICC
stage IIB. He died due to recurrence and rapid progression
of the cancer at two months after surgery.
OCUP-A2
A man in his 30s with left upper quadrant pain was
diagnosed by CT as having a malignant pancreatic neo-
plasm with liver metastasis. The values of CEA, CA19-9,
SPan-1 were 0.7 ng/mL, 394 U/mL and 60 U/mL, respect-
ively. Although the diagnosis was unresectable pancreatic
cancer, the patient underwent distal pancreatectomy in
order to control the bleeding in his stomach caused by the
invading primary tumor. The pathological classification of
the cancer was T4NXM1, UICC stage IV. After surgery,
the patient was treated with gemcitabine. Although his
activities of daily living had improved at the beginning of
chemotherapy, he died five months after surgery due to
progression of the cancer.
The histological diagnosis in both cases was determined
as the pleomorphic type of anaplastic pancreatic cancer
because tissue imaging with hematoxylin and eosin (H&E)
staining was composed of a large portion of pleomorphic
cells and a portion of spindle cells and poorly differen-
tiated adenocarcinoma in the pancreas.
Establishment of cell lines and cell culture
Samples of the patients’ ascites were removed in CELL-
STAR® tubes (Greiner Bio-One GmbH, Frickenhausen,
Germany) and centrifuged at 1500 rpm for 5 min. The
pellets were suspended in Dulbecco’s Modified Eagle’s
Medium (DMEM; Wako, Osaka, Japan) containing
10 % heat-inactivated fetal bovine serum (FBS; Nichirei
Biosciences, Tokyo, Japan), 100 IUmL−1 penicillin
(Sigma, Steinheim, Germany), 100 μgmL−1 streptomycin
(Sigma), and 0.5 mM sodium pyruvate (Sigma). Then, the
pellets were plated into a 100-mm culture dish (Falcon,
Becton-Dickinson Labware, Lincoln Park, NJ, USA) and
cultivated at 37 °C in a humidified atmosphere with 5 %
CO2. The cell lines were trypsinized every 7–10 days, and
maintained in complete culture medium. PDA cell lines
(Panc-1, MIAPaCa-2, RWP-1, SW1990) and breast cancer
cell line (MCF-7) were purchased from American Type
Culture Collection (ATCC; Manassas, VA, USA) for use
in various assays. As above, these cell lines were also
cultured and passed. The morphological findings on
OCUP-A1 and OCUP-A2 were investigated by phase-
contrast microscopy.
Short tandem repeat (STR) genotyping
Short tandem repeat genotyping was performed using
genomic DNA extracted from OCUP-A1 and OCUP-A2.
This analysis was performed by Promega (Tokyo, Japan).
This experiment was conducted using the PowerPlex® 16
System (Promega, Madison, WI, USA) according to the
manufacturer’s instructions.
Karyotype analysis
G-banding was performed by SRL, Inc. (Tokyo, Japan)
via the manufacturer’s procedures. The cells of OCUP-A1
and OCUP-A2 were cultured until exponential prolifera-
tion was reached for this analysis. Then, the cells were
treated with colcemid (0.02 μg/mL) for 60 min and hypo-
tonic treatment by potassium chloride (0.075 mol/L) for
20 min at 37 °C. The cells were fixed by Carnoy’s solution
(methanol: acetic acid = 3: 1 by volume) for 10 min. The
slides were air-dried and analyzed via G-banding. G-
banding was carried out by trypsinizing the slides and
stained by Giemsa staining using laboratory procedures.
The slides were analyzed with the iCas system (Flovel
Company, Ltd., Tokyo, Japan), and the images of the
metaphases were captured. Using approximately 50 cells in
both cell lines, the number of chromosomes was counted.
Ten cells that resembled the mode number were karyo-
typed in detail.
DNA extraction
Genomic DNA samples of OCUP-A1 and OCUP-A2
were extracted using the QIAamp® DNA Mini Kit (Qiagen,
Venlo, Netherlands) according to the manufacturer’s
protocol. The NanoDrop system (Invitrogen, Carlsbad,
CA, USA) quantified the extracted DNA and estimated
the quality before sequencing.
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Deep sequencing using Ion AmpliSeq™ cancer hotspot
panel v2
The Ion AmpliSeq™ Cancer Hotspot Panel v2 (Life Tech-
nologies, Carlsbad, CA, USA) was used as multigene panels
for sequencing. The amplicon library for exploring hotspot
mutations of 50 cancer-related genes was generated using
10 ng of DNA from each sample. The 50 genes were as
follows: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1,
CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4,
EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11,
GNAS, GNAQ, HNF1A, HRAS, IDH1, JAK2, JAK3,
IDH2, KDR/VEGFR2, KIT, KRAS, MET, MLH1, MPL,
NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN,
PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC,
STK11, TP53, and VHL. Multiplex polymerase chain
reaction amplification was conducted with 10 ng of
DNA samples to make the sequence library according
to the Ion AmpliSeq™ Library Preparation kit (Rev. A. 0
Jan 2014, Life Technologies). The quality of the library
was estimated by the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). After emulsion
PCR, sequencing was run on the Ion PGM™ system
(Life Technologies). The Torrent Suite™ software pro-
gram v 4.0.2 (Life Technologies) was used to analyze
the data, including alignment of the sequences to the
reference genome (human genome build 19) and base
calling. Variants were detected by the Torrent Variant
Caller plug-in v 4.0-r76860 (Life Technologies) and visual-
ized by the Integrative Genomics Viewer (Broad Institute,
Cambridge, MA, USA). These procedures were consigned
to TaKaRa Bio, Inc. (Otsu, Shiga, Japan). For a reliable se-
quence variant, a sequencing coverage of 250× and a vari-
ant frequency of at least 10 % in the background of the
wild type were used as minimum requirements in the
current study, as well as in the previous study [12].
Proliferation
For estimation of proliferation, the doubling times of
OCUP-A1, OCUP-A2 and 4 PDA cell lines were mea-
sured. A 6-well plate was used to culture these cell lines.
There were 1.5 × 105 cells per well that were disseminated
and incubated at 37 °C in a humidified atmosphere with
5 % CO2. When the cell number count was performed,
monolayer cells were trypsinized. The cell number was
counted every 24 until 96 h after the beginning of culture.
The Bio-Rad TM10™ automated cell counter (Bio-Rad
Laboratories, Hercules, CA, USA) was used. The doubling
time was determined from the growth curve obtained by
the count.
Migration and invasion
The migratory and invasive abilities were estimated
using the IncuCyte ZOOM (Essen BioScience, Tokyo,
Japan). These assays were performed according to the
manufacturer’s protocol. Before assay, each pancreatic
cancer cell line was cultured in a 96-well plate, and in-
cubated until semi-confluent in 5 % CO2 at 37 °C.
Then, the 96-pin WoundMaker™ (Essen BioScience)
created a wound in each well of the 96-well plate. After
washing by phosphate buffered saline (PBS), DMEM +
2%FBS was added into each well, and the plate was
placed into the IncuCyte. The scratched area was
scanned with the IncuCyte™ Live-Cell Imaging System
and software (Essen BioScience) every 3 h. With the inva-
sion assay, each pancreatic cancer cell line was cultured
on Matrigel® (Corning, Inc, Corning, NY, USA) in a 96-
well plate then incubated until semi-confluent in 5 % CO2
at 37 °C. After washing with PBS, DMEM+ 2%FBS and
Matrigel® of the same quantity as the medium were added.
Similarly to the migration assay, the scratched area was
scanned with the IncuCyte™ Live-Cell Imaging System and
software (Essen BioScience) every 3 h.
Chemosensitivity
To estimate the effect of anti-cancer drugs on the
viability of the 6 pancreatic cancer cell lines, a 3- (4, 5-
dimethylthiazol-2-yl) - 2, 5- diphenyltetrazolium bromide
(MTT, Wako, Osaka, Japan) colorimetric assay was per-
formed. The cancer cells (5 × 103 cells/well) were seeded
into a 96-well plate in DMEM. After 24 h, a different con-
centration of anti-cancer drugs was added to each well.
Furthermore, after incubation for 72 h at 37 °C, 10 μL of
MTT (5 mg/mL in PBS) were added to each well and the
plates were incubated at 37 °C for 3 h, and then 200 mL of
dimethyl sulfoxide (Wako) was added. The formazan
product of MTT was measured as the absorbance at
550 nm using a microtiter plate leader (Model 550; Bio-
Rad Laboratories, Tokyo, Japan). The percentage of cell
viability was determined as the ratio of the absorbance
of the sample to control. The IC50 value was measured
as the drug concentration showing 50 % cell growth inhib-
ition compared with the control cell proliferation in the 6
cell lines. The anti-cancer drugs used were 5-fluorouracil
(5-FU; Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan), gem-
citabine (GEM; Yakult Honsha Co., Ltd., Tokyo, Japan),
irinotecan (IRI; Yakult Honsha), oxaliplatin (OXA; Yakult
Honsha), and paclitaxel (PTX; Nippon Kayaku Co., Ltd.,
Tokyo, Japan).
Tumor markers and VEGF secreted from cell lines
There were 106 cells of each cell line that were cultured
in 10 mL of DMEM+ 5%FBS for 4 days. Each supernatant
was used for measuring the levels of CEA, CA19-9, SPan-1,
DUPAN-2, and vascular endothelial growth factor (VEGF).
These 4 tumor markers are generally measured for
PDA patients. CEA was estimated by immunoassay
(ARCHITECT® CEA, Abbott Japan, Tokyo, Japan).
CA19-9 was investigated by chemiluminescent enzyme
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immunoassay (Kemirumi ACS-CA19-9 II, Siemens Japan,
Tokyo, Japan). SPan-1 was measured by immunoradio-
metric assay (SPan-1 RIA Beads, TFB, Inc, Tokyo, Japan).
DUPAN-2 and VEGF were investigated by enzyme-linked
immunosorbent assay (ELISA) (DUPAN-2: Detamina-
DUPAN-2, Kyowa Medex Co., Ltd., Tokyo, Japan; VEGF:
Human VEGF Quantikine ELISA Kit, R&D Systems,
Minneapolis, MN, USA). These analyses were conducted
according to each manufacturer’s method by the Mitsubishi
Chemical Medience Corporation, Tokyo, Japan.
Angiogenesis (tube formation) assay
Angiogenesis affected by cancer cells was investigated
using the CellPlayer™ Angiogenesis PrimeKit (Essen
BioScience). This assay was performed according to the
manufacturer’s method. Before starting the assay, 106
cells of each cell line were cultured in 10 mL of
DMEM + 5%FBS for 4 days. The supernatant was added
to co-cultured green fluorescent protein-labeled human
umbilical vein endothelial cells (HUVECs) and normal
human dermal fibroblasts in a 96-well plate, and then
HUVEC tube formation was monitored using IncuCyte
ZOOM (Essen BioScience). As negative and positive con-
trol of angiogenesis, 5%DMEM and VEGF (4 ng/mL) were
used instead of the supernatant of each cell line, re-
spectively. The medium was replaced on days 5, 7, and
9 after cell plating. Phase-contrast and fluorescent im-
ages of tube formation were automatically captured,
and tube length and branch points were also automatically
measured every 6 h for 10 days using IncuCyte ZOOM
(Essen BioScience). Kinetic plots of the angiogenesis
metrics (tube length, tube area, and branch points) could
be formed using the IncuCyte software.
Proliferation under hypoxia
For investigating the proliferation of OCUP-A1 and
OCUP-A2 under low oxygen condition, the growth of
each cell line was compared between normoxia and hyp-
oxia. Cancer cells (5 × 103 cells/well) in DMEM+ 10%FBS
were seeded into a 96-well plate and incubated at 37 °C in
a humidified atmosphere with 5 % CO2 and 1 or 21 % O2.
Using IncuCyte ZOOM (Essen Bio-Science), two images
per well were captured in both phase-contrast and fluor-
escence every 3 h during 48 h. The proportions of the
fluorescent areas to all areas in the images were measured
by the software under both hypoxia and normoxia. The
fluorescent areas were regarded as indicating cell growth.
Then, the cell viability under hypoxia at 48 h was calcu-
lated considering the cell viability under normoxia at 48 h
as control in each cell line.
Western blotting
Proteins expressions of E-cadherin (epithelial marker)
and vimentin (mesenchymal marker) of OCUP-A1 and
OCUP-A2 were examined by Western blotting. Ap-
proximately 30 μg of protein extracts were separated
through 10 % sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto a
polyvinylidene difluoride membrane using the Trans-
Blot® Turbo™ Transfer System (Bio-Rad Laboratories,
Inc., Hercules, CA, USA). Then, using the SNAP i.d.®
2.0 system (Merck Millipore, Darmstadt, Germany),
the membranes underwent application of Tris-buffered
saline-Tween (TBS-T) solution containing each pri-
mary antibody against anti-rabbit E-cadherin (1:300,
Cell Signaling Technology, Danvers, MA, USA), anti-
rabbit vimentin (1:300, Cell Signaling Technology),
and anti-mouse β-actin (1:2500, Sigma-Aldrich, St.
Louis, MO, USA) for 10 min after blocking with ECL
blocking agent (GE Healthcare Life Sciences, Little
Chalfont, Buckinghamshire, UK) and incubated with
HRP-conjugated anti-mouse or anti-rabbit secondary
antibody (1:5000, Sigma-Aldrich) for 10 min. Protein
bands were visualized with the Luminescent Image
Analyzer LAS 4000-plus (Fuji, Tokyo, Japan).
Side population (SP) analysis using flow cytometry
Stem-like cells were measured by SP analysis. The cells
were incubated in pre-warmed DMEM supplemented
with 5 % FBS containing 5 μg/mL Hoechst 33342 (Sigma
Chemicals, St Louis, MO, USA) in the absence or pres-
ence of 30 μg/mL verapamil at 37 °C for 60 min. Then,
1 μg/mL propidium iodide was added and then filtered
through a 40-μm cell strainer (Becton Dickinson, San
Diego, CA, USA) and maintained at 4 °C. The analysis
was performed using FACS AriaII (Becton Dickinson).
Hoechst 33342 was excited with the UV laser at 350 nm,
and fluorescence emission was measured with 405/BP30
(Hoechst blue) and 570/BP20 (Hoechst red) optical filters.
Tumorigenicity in vivo
There were 107 viable cells of each cell line (OCUP-A1,
OCUP-A2, Panc-1, and MIAPaCa-2) that were suspended
by 200 μL of DMEM+ 10%FBS and were inoculated sub-
cutaneously into the back of four-week-old BALB/c nude
mice. In each cell line, five mice were injected subcutane-
ously. In all cases, the injected cells developed a subcuta-
neous tumor. During approximately one month, the
diameter of the subcutaneous tumor in each mouse was
measured every 3–5 days. The volume of the tumor was
calculated with the formula:
Tumor volume mm3
  ¼ long diameter mmð Þð Þ
 short diameter mmð Þð Þ2
 0:5
The mice were sacrificed with an overdose of sevoflur-
ane. Part of each subcutaneous tumor was fixed in 10 %
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formalin and embedded in paraffin section for staining
and immunohistochemistry.
Immunohistochemistry
Tissues from primary APC were obtained from the 2
study patients who underwent surgery at our institution.
Then, the xenografts of OCUP-A1 and OCUP-A2 were
also used for immunohistochemistry. Formalin-fixed
paraffin-embedded specimens were made from each tis-
sue sample. In each sample, the representative block of
APC and the cell lines were chosen. Each block was
sliced at 4 μm for H&E staining and immunohistochemis-
try for E-cadherin and vimentin. Immunohistochemistry
was performed according to the protocol of our institution.
We used antibodies against E-cadherin (1: 200, Abcam,
Cambridge, UK) and vimentin (1: 200, Dako, Glostrup,
Denmark) for immunohistochemical labeling. The ex-
pression of each protein was scored as 0 (no labeling in
cancer cells), 1+ (mild labeling), 2+ (moderate labeling),
and 3+ (strong labeling). The scoring was performed by
two surgeons and a pathologist.
Statistical analysis
Results of statistical analyses were expressed as the
means ± standard error from at least three independent
experiments. Significance of difference was analyzed
with Student’s t tests or Tukey’s honest significant differ-
ence (HSD) test using JMP 10 (SAS Institute, Inc., Cary,
NC, USA). P-values less than 0.05 were regarded as sta-
tistically significant.
Results
Morphology of new established cell lines, OCUP- A1 and
OCUP- A2
We succeeded in establishing the cell lines of OCUP- A1
and OCUP- A2. Although both cell lines had little adhe-
sion in a non-confluent state, they formed monolayer
sheets in confluence. The cells of OCUP- A1 were mainly
spindle-shaped, and appeared as if they were extended
for communication among the cancer cells (Fig. 1a). In
addition, a few polygonal and large cells were observed
in the cell line. Many cells of OCUP- A2 were polygonal
and formed clusters by adhesion among the cancer cells.
Fig. 1 Photographs of the two established anaplastic pancreatic cancer cell lines taken by the phase-contrast microscope. a OCUP-A1.
(original magnification × 100). b OCUP-A2. (original magnification × 100)
Fig. 2 Representative karyotype analysis of the two established anaplastic pancreatic cancer cell lines using the G-banding method. The figure
displays the chromosome construction of OCUP-A1 (Fig. 2a) and OCUP-A2 (Fig. 2b). The arrow designates the reconstructive chromosome. The
marker chromosome is different from standard diploid and has a break point
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In addition, a few round cells were observed in OCUP- A2
(Fig. 1b).
STR assay
All DNA extracted from the 2 established cell lines
showed identical STRs, which did not corresponding to
the cells of the database of the Japanese Collection of
Research Bioresources (JCRB) (Database of 2279 cells
registered in the ATCC, the Deutsche Sammlung von
Mikroorganismen und Zellkulturen, and the Japanese
Collection of Research Bioresources).
Chromosome analysis
The chromosome number of OCUP- A1 ranged from
55 to 106. The range of chromosome numbers of
OCUP- A2 was 74 to 79. Figure 2 shows a representa-
tive karyotype of both cell lines. Both cell lines had
many chromosomal abnormalities in the number and
structure. An abnormality in OCUP- A1 was identified:
add(4) (q21), +5, +add(6) (q13) x2, del(6) (q?) x2,del(7)
(q22) (q13), −10, −11, −15, −15, −16, −16, +18, −21,
add(22) (q13), +mar1, +mar2, +mar3x3, +5mar. A
chromosomal abnormality in OCUP- A2 was: +del(X)
(q?), +1, +der(1;15) (p10;q10) x2, der(1;19) (q10;p10),
der(1;19) (q10;p10), der(2) t(2;7) (p11.2;q11.2), del(4)
(q?), +6, +7, +10, +11, add(13) (p11.2) x2, add(14)
(p11.2) x2, der(14;18) (q10;q10), −15, +16, add(17)
(p11.2)x2, −18, −18, +19, add(21) (p11.2), add(22)
(p11.2)x3, +mar1, +mar2, +mar3, +mar4.
Gene analysis
A sufficient library from each sample led to subsequent
successful sequencing. In DNA samples of OCUP-A1
and OCUP-A2, a mean 100× coverage of 98.8 % and
97.3 % with a mean read length of 105 bp was obtained,
respectively.
Thirteen gene mutations of the targeted genes were
identified in both cell lines (Table 1). 9 gene mutations
(ERBB4, FGFR3, PDGFRA, KDR, APC, KRAS, FLT3,
TP53, and STK11) were common to each cell line. The
sequence variations of these mutations were all single
nucleotide polymorphisms, except for one of the TP53
mutations identified in OCUP-A1. KRAS mutations
were in codon 12 in both samples. TP53 mutations con-
sisted of various variations including three novel muta-
tions: g.7578222_7578225del, g. 7578369 A > C, and g.
7579472 G > C. Most of the other detected mutations
were newly identified, whereas the mutations of PIK3CA
and CSF1R were detected only in OCUP-A1. Similarly,
the mutations of ALK and RET were identified only in
OCUP-A2.
Proliferation
Table 2 shows the doubling times of the 6 cell lines in-
cluding OCUP- A1 and OCUP- A2. The doubling times
of OCUP-A1 and OCUP-A2 did not have prominently
short doubling times compared to other PDA cell lines.
Migration assay and invasion assay
Figure 3 shows the wound closure proportion (relative
wound density; RWD) as migration or invasion abilities
of each cell line every 3 h from starting the test to 24 h.




2 ERBB4 g. 212812097 T > C
(54.2 %)
g. 212812097 T > C
(18.4 %)
2 ALK - g. 29432625 C > A
(16.4 %)
3 PIK3CA H1047R (77.3 %) -
4 FGFR3 g. 1807894G > A
(100 %)
g. 1807894G > A
(100 %)
4 PDGFRA V824V (97.5 %) g. 55141055 A > G
(100 %)
g. 55141055 A > G
(100 %)
4 KDR g. 55980239 C > T
(99.0 %)
g. 55980239 C > T
(100 %)
5 APC g. 112175770 G > A
(97.7 %)
g. 112175770 G > A
(96.9 %)
5 CSF1R g. 149433596 G > A
(99.5 %)
-
g. 149433597 C > T
(95.3 %)
10 RET - g. 43613843 G > T
(63.5 %)
12 KRAS G12D (98.5 %) G12R (57.3 %)
13 FLT3 g. 28610183 A > G
(100 %)
g. 28610183 A > G
(100 %)
17 TP53 R209fs*6 (50.3 %)
D208E (99.6 %)




g. 7579472 G > C
(92.3 %)
19 STK11 g. 1220321 T > C
(42.0 %)
g. 1220321 T > C
(100 %)
Gene mutations were examined with Ion AmpliSeq™ Cancer Hotspot Panel v2
Table 2 Doubling time in pancreatic cancer cell lines
Cell line Doubling time (hours)
OCUP-A1 20.6 ± 1.2
OCUP-A2 20.6 ± 1.4
Panc-1 25.8 ± 2.8
MIAPaCa-2 25.7 ± 4.3
RWP-1 23.6 ± 0.54
SW1990 35.8 ± 4.4
OCUP-A1 and OCUP-A2 vs SW1990; p < 0.05
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In the migration assay, the RWD at 24 h of OCUP-A1
was significantly superior to that of OCUP-A2, Panc1
and MIAPaCa2, but inferior to that of RWP1 and
SW1990. Then, the RWD at 24 h of OCUP-A2 was sig-
nificantly lowest in all 6 cell lines. In the invasion assay,
the RWD at 24 h of OCUP-A1 was significantly superior
to that of OCUP-A2, RWP1 and Panc1, but inferior to
that of SW1990. The RWD at 24 h of OCUP-A2 was
significantly lower than that of OCUP-A1 and SW1990.
Drug sensitivity
The IC50 values of each cell line are shown for each
anti-carcinogenic agent in Table 3. Both of OCUP-A1
and OCUP-A2 showed relatively high chemosensitivity
to GEM. OCUP-A1 showed relatively low sensitivity to
5-FU. OCUP-A2 showed the highest sensitivities to IRI
and OXA among 6 cell lines tested. OCUP-A2 was also
relatively sensitive to 5-FU and PTX.
Tumor markers secreted from cell lines
The values of tumor markers in the supernatant of the
cell lines are shown in Table 4. OCUP-A1 and OCUP-A2
did not much secrete any of tumor markers.
Angiogenesis and VEGF secreted from cell lines
As seen in Fig. 4, HUVEC showed cord extension ac-
cording to the addition of supernatant of cultured cancer
cells or VEGF control. The cord extension of each sam-
ple was evaluated using tube length per unit area, indi-
cating induction of angiogenesis. The supernatant of all
cell lines gradually caused tube extension of HUVEC. At
day 8, the supernatant of OCUP-A1, OCUP-A2, Panc1,
MIAPaCa2 and positive control (VEGF administration)
extended the tube length to 5.16 ± 0.23, 3.75 ± 0.070,
1.77 ± 0.16, 3.58 ± 0.33 and 4.33 ± 0.052 mm/mm2, re-
spectively. However, negative control (FBS included in
the supernatant) hardly caused cord extension (tube length
Fig. 3 Migration and invasion of pancreatic cancer cell lines. Relative wound density designates the percentage of scratch area where cancer
cells migrated or invaded
Table 3 IC50 values of anti-cancer drugs for pancreatic cancer cell lines
Drug 5-FU (μM) GEM (nM) IRI (μM) OXA (μM) PTX (nM)
OCUP-A1 51.1 ± 5.1 6.60 ± 1.4 5.21 ± 0.20 17.6 ± 0.94 15.7 ± 0.60
OCUP-A2 23.8 ± 6.3 6.01 ± 0.60 1.67 ± 0.075* 1.63 ± 0.070* 3.63 ± 0.14*
Panc-1 24.2 ± 12 59.2 ± 5.5*** 8.90 ± 0.49*** 9.25 ± 1.4 27.8 ± 0.95***
MIAPaCa-2 10.7 ± 2.4* 24.0 ± 10*** 15.3 ± 0.28*** 20.1 ± 0.91** 6.92 ± 0.14*,**
RWP-1 11.6 ± 1.8* 4.45 ± 1.3 7.02 ± 0.50*** 18.4 ± 0.88 3.45 ± 0.046*
SW1990 68.2 ± 15** 92.0 ± 4.3*** 10.5 ± 0.47*** 72.9 ± 6.8*** 21.3 ± 0.86***
5-FU 5-fluorouracil, GEM gemcitabine, IRI irinotecan, OXA oxaliplatin, PTX paclitaxel
*vs OCUP-A1; p < 0.05
**vs OCUP-A2; p < 0.05
***vs OCUP-A1 and OCUP-A2; p < 0.05
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at day 8; 0.14 ± 0.019 mm/mm2). The culture supernatant
of OCUP-A1 and OCUP-A2 significantly contributed to
longer cord extension than Panc-1. The value of VEGF in
the supernatant of each cell line were shown in Fig. 4. All
cell lines secreted VEGF, and OCUP- A1 showed the
maximum secretion of VEGF among the 4 cell lines.
Proliferation under hypoxia
Figure 5 shows that OCUP- A1 was the only cell line
that did not significantly change proliferation between
hypoxia and normoxia. The proliferation of OCUP-A2
significantly decreased by approximately 20 % under
hypoxia compared to normoxia. And the proliferations
under hypoxia of other cell lines also significantly de-
creased by about 25 to 40 % compared to under normoxia.
Western blotting
The protein bands of OCUP-A1 and OCUP-A2 were
compared with that of the breast cancer cell line MCF7,
which was known to expresses E-cadherin (Fig. 6). Both
OCUP-A1 and OCUP-A2 expressed vimentin but did
not express E-cadherin, while MCF7 showed the expres-
sion of E-cadherin and the absence of vimentin.
SP cell analysis
Figure 7a is a representative picture of flow cytometric
analysis. The fraction of SP cells is enclosed by the white
line (upper panel) and disappeared under the presence
of verapamil (bottom panel). The percentage of the total
cells is shown close to the white line. The average SP
percentages of OCUP-A1, OCUP-A2, Panc-1 and MIA-
PaCa2 were 1.8 ± 0.28 %, 1.7 ± 0.12 %, 1.1 ± 0.20 % and
0.6 ± 0.058 %, respectively (Fig. 7b). The proportion of
SP cells in OCUP-A1 and OCUP-A2 was significantly
higher than that in MIAPaCa2.
Tumorigenicity of OCUP- A1 and OCUP- A2 in nude mice
In all cell lines, xenografts were successfully made from
all mice. Figure 8 shows the growth curve of the xeno-
grafts of the four cell lines. At 29 days after injection, the
tumor volume of the xenograft of OCUP-A2 increased
significantly more than that of Panc-1 and MIAPaCa2.
The tumor size of the mice given an injection of OCUP-
A1 was also significantly larger than that of Panc-1. The
volume did not statistically differ between OCUP-A1 and
OCUP-A2.
Immunohistochemical staining of epithelial-mesenchymal
transition (EMT)-related markers
Immunohistochemical stainings of the primary tumor
and the xenograft of OCUP-A1 and OCUP-A2 were
negative for E-cadherin, but almost positive for vimentin
(Fig. 9). The expression patterns of these proteins in
OCUP-A1 and OCUP-A2 were similar to those in western
blotting.
Discussion
Due to the rarity, the characteristics of APC are not well
documented. The present study intended to clarify the
biological behaviors of APC using two novel APC cell
lines established in our institute, compared to conven-
tional PDA. It may create an important role for future
pancreatic therapy.
Conventional chromosomal analysis has drawn attention
to significant implications of common chromosomal aber-
rations in pancreatic cancer [13]. The chromosomal ana-
lyses performed in the present study identified numerical
Table 4 Tumor markers in supernatant of pancreatic cancer
cell lines
CEA CA19-9 SPan-1 DUPAN-2
(ng/mL) (U/mL) (U/mL) (U/mL)
OCUP-A1 <0.5 <1.2 <3 <25
OCUP-A2 <0.5 <1.2 <3 <25
Panc-1 <0.5 <1.2 <3 <25
MIAPaCa2 <0.5 <1.2 <3 <25
RWP1 24.6 3020 865 24.6
SW1990 2.8 4720 2050 2.8
CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9
Fig. 4 Tube formation of human umbilical vein endothelial cells with vascular endothelial growth factor (VEGF) stimulation derived from cell lines
and the values of VEGF in supernatant of pancreatic cancer cell lines
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and unbalanced structural abnormalities in both cell lines
such as loss of chromosome Y or/and chromosome 18,
which are frequently seen in pancreatic cancer [13]. How-
ever, the chromosomal aberrations of these two cell lines
did not correspond to chromosomal aberrations of other
APC samples [14]. The various aberrations in APC might
demonstrate the heterogeneity and biological complexity
of APC.
Regarding gene mutation analysis, there were common
and different features between APC and PDA. Mutations
of KRAS and TP53 were identified in OCUP-A1 and
OCUP-A2. Although these mutations have been re-
ported most frequently in ordinary PDA [15, 16] and in
APC [6, 7], the SMAD4 mutation that was also observed
in PDA [15, 16] was not detected in both cell lines. It is
unclear whether the established cell lines only happened
to be composed of cells that had no mutation of SMAD4,
or whether APC itself expresses the wild type of the gene;
these mutations have seldom been reported in APC, un-
like the mutations of KRAS and TP53. As a mutation of
low frequency in PDA, the STK11 mutation [2, 16, 17]
was also found in both cell lines. In addition, although we
detected genetic alterations of the genes STK11 and APC
(adenomatous polyposis coli), which are related to genetic
syndromes associated with familial pancreatic cancer such
as Peutz-Jeghers syndrome or familial adenomatous polyp-
osis [17], it is unknown whether the mutations were germ-
line mutations because of not investigating the genes in
their normal tissues. From the current sequencing, it is
suggested that the progression of APC might be related to
many complicated mutations.
Several assays were performed for investigating the ag-
gressiveness of APC using the experimental model in
the present study. The results demonstrated that APC
cell lines did not have prominent abilities of proliferation,
migration and invasion compared to other PDA cell lines
in vitro. However, the tumorigenicity in vivo of OCUP-A2
was stronger than that of MiaPaca-2 and Panc-1 and that
of OCUP-A1 was also stronger than that of Panc-1. These
results were consistent with its clinical characteristics that
APC often develops huge tumor. The average size in most
series of APC has been reported to be 9 or 10 cm. [8]
We hypothesized that the high proliferation ability in
vivo and in clinical observation might arise from the
tumor microenvironment and increment of stem-like
cells. Therefore, we performed assays for the angiogen-
esis, hypoxic tolerance and SP cells. The cord formation
of HUVEC and production of VEGF showed that angio-
genesis of OCUP-A1 was superior to that of other PDA
cell lines resulting from the higher production of VEGF.
Previous studies have suggested that VEGF and its recep-
tors (VEGFR) contribute to an autocrine/paracrine mito-
genic loop via mitogen-activated protein kinase (MAPK)
signaling on the proliferation of cancer cells, including
pancreatic cancer, besides the stimulation of angiogenesis
[18–20]. The secretion of VEGF from OCUP-A1 might
play a role in active proliferation in vivo. Further examin-
ation is needed on whether VEGFRs are actually expressed
on APC cell lines because we only observed a single
Fig. 5 Regarding confluence incubated under hypoxic condition as standard value, the confluence under hypoxic condition was compared with
the confluence under normoxic condition in each cell line
Fig. 6 Western blot analysis of E-cadherin and vimentin of OCUP-A1
and OCUP-A2. MCF7 was used as positive E-cadherin and negative
vimentin controls
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Fig. 7 Analysis of side population (SP) cells in pancreatic cancer cell lines. a Representative figure of flow cytometry. The fraction of SP cells in
each cell line is outlined by the white line. Each cell line was stained with Hoechst 33342 in the presence or absence of verapamil (shown as bottom
panel or upper panel, respectively). SP cells disappeared with verapamil. b The percentage of SP fraction in each cell line
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nucleotide polymorphism (SNP) of KDR (VEGFR-2) on
gene analysis.
The high malignancy of APC might also be related to
hypoxia. The present study indicated that OCUP-A1 had
hypoxia tolerance. Hypoxia tolerance could be formed
through a gene mutation such as a p53 mutation, which
relates to apoptosis, and the interaction between onco-
genic signaling such as RAS and hypoxia-induced tran-
scription factor (HIF) 1α [21]. It has also been reported
that hypoxia enhances vascular endothelial cell growth
[22]. Another previous report specifically showed that
HIF-1 moderated VEGF transcription [23]. As a result,
angiogenesis is induced by hypoxia, and then the above-
mentioned autocrine mitogen for APC cells might be
promoted, resulting in active proliferation in vivo and in
clinical observation. In addition, it has been demonstrated
that hypoxia is related to aggressive growth in pancreatic
cancer using a xenograft model [24]. Future studies may
be able to investigate whether hypoxia-induced aggressive
growth correlates with the extent of gene mutation or
VEGF expression in vivo.
SP cells in APC cell lines were more enriched than in
MiaPaCa-2. Previous studies on SP analysis showed that
SP cells related to tumorigenic potential and drug
resistance, such as cancer stem cells in various type of
tumors [25]. Especially in a pancreatic cancer cell line,
to date, it has also been suggested that SP cells might
contribute to aggressive tumor growth [26].
To sum up, these results suggested the biological ag-
gressiveness of APC might be related with induction of
angiogenesis, acquisition of tolerance to hypoxia, and in-
crement of stem-like cells.
Chemosensitivity analysis showed that OCUP-A1 and
OCUP-A2 were comparatively sensitive to several anti-
cancer drugs including gemcitabine. OCUP-A2 was also
the most sensitive to some of anti-cancer drugs among
the examined cell lines. Strobel et al. reported that adju-
vant or palliative chemotherapy did not contribute to im-
provement of prognosis in APC [3]. However, a different
study demonstrated that paclitaxel treatment, which
was selected by chemosensitivity examination, resulted
in complete response to APC [10]. Furthermore, it has
been reported that a subtype of PDA, which has highly
expressed mesenchyme-associated genes, was more sensi-
tive to gemcitabine than the classical type of this neo-
plasm [27]. The present study also suggested that selective
use of anti-tumor drugs might even enable the aggressive-
ness of APC to be controlled.
Regarding EMT, the absence of E-cadherin and the ex-
pression of vimentin were observed in APC cell lines,
xenografts and primary specimens from western blotting
or immunohistochemistry. This is a feature of APC path-
ology [8, 28]. In pancreatic cancer, it has been reported
that patients with absence of E-cadherin expression or the
expression of vimentin had poorer prognosis than patients
with the differentiated type [29, 30]. In addition, it has also
been reported that the combination of these protein ex-
pression patterns was correlated with prognosis in pancre-
atic cancer patients [31]. In the present study, both
patients from whom the two established cell lines were
derived had very poor prognosis. OCUP-A1 and OCUP-
A2 also reflected the high malignancy of primary tumor in
terms of EMT status.
Fig. 8 Growth curve of xenografts of pancreatic cancer cell lines (n= 5).
Tumors developed in all mice using for this assay
Fig. 9 Immunostaining of primary tumor and xenograft in OCUP-A1 and OCUP-A2. All specimens showed loss of E-cadherin expression and gain
in vimentin expression. The expression pattern was consistent with the epithelial-mesenchymal transition (EMT) phenotype (original magnification × 400)
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The present study was limited in two respects. One
limitation was that these cell lines were samples derived
from ascites. Therefore, OCUP-A1 and OCUP-A2 might
lose the properties possessed in the primary site. An-
other limitation was the monoclonality of the cell lines
OCUP-A1 and OCUP-A2 that could not reflect hetero-
genic properties of the pleomorphic type of APC. To re-
solve these limitations, a new APC cell line derived from
a primary site needs to be established and then divided
into several cell types using limiting dilution.
Conclusion
The present study succeeded in establishing two APC
cell lines. Angiogenesis, hypoxia tolerance, the presence
of SP cells and EMT might be associated with the biology
of APC. These cell lines could be useful for investigating
the progression of pancreatic cancer. Effective treatment
for APC could potentially be developed through further
investigations using these cell lines.
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